VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection)

Background— The haplotypes in the gene vitamin K epoxide reductase complex subunit 1 (VKORC1) have been found to affect warfarin dose response through effects on the formation of reduced-form vitamin K, a cofactor for &ggr;-carboxylation of vitamin K–dependent proteins, which is involved in the coagulation cascade and has a potential impact on atherosclerosis. We hypothesized that VKORC1-dependent effects on the coagulation cascade and atherosclerosis would contribute to susceptibility for vascular diseases. Methods and Results— To test the hypothesis, we studied the association of polymorphisms of VKORC1 with stroke (1811 patients), coronary heart disease (740 patients), and aortic dissection (253 patients) compared with matched controls (n=1811, 740, and 416, respectively). Five common noncoding single-nucleotide polymorphisms of VKORC1 were identified in a natural haplotype block with strong linkage disequilibrium (D′>0.9, r2>0.9), then single-nucleotide polymorphism (SNP) +2255 in the block was selected for the association study. We found that the presence of the C allele of the +2255 locus conferred almost twice the risk of vascular disease (odds ratio [OR] 1.95, 95% confidence interval [CI] .58 to 2.41, P<0.001 for stroke; OR 1.72, 95% CI 1.24 to 2.38, P<0.01 for coronary heart disease; and OR 1.90, 95% CI 1.04 to 3.48, P<0.05 for aortic dissection). We also observed that subjects with the CC and CT genotypes had lower levels of undercarboxylated osteocalcin (a regulator for the bone), probably vascular calcification, and lower levels of protein induced in vitamin K absence or antagonism II (PIVKA-II, a des-&ggr;-carboxy prothrombin) than those with TT genotypes. Conclusions— The haplotype of VKORC1 may serve as a novel genetic marker for the risk of stroke, coronary heart disease, and aortic dissection.

[1]  M. Matsuoka.  [Coagulation factors]. , 1961, Jibi inkoka Otolaryngology.

[2]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[3]  P. Fernlund,et al.  Vitamin K dependent modifications of glutamic acid residues in prothrombin. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[4]  E. Falk.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.

[5]  P. Reitsma,et al.  The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. , 1991, Blood.

[6]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[7]  P. Fitzgerald,et al.  Contribution of Localized Calcium Deposits to Dissection After Angioplasty: An Observational Study Using Intravascular Ultrasound , 1992, Circulation.

[8]  E. Puffenberger,et al.  Marfan phenotype variability in a family segregating a missense mutation in the epidermal growth factor-like motif of the fibrillin gene. , 1992, The Journal of clinical investigation.

[9]  W. Lawson,et al.  Vitamin K-dependent clotting factors are elevated in young adults who have close relatives with ischemic heart disease. , 1993, The Journal of laboratory and clinical medicine.

[10]  W D Wagner,et al.  A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[11]  M. Bots,et al.  Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. , 1995, Atherosclerosis.

[12]  R E Pyeritz,et al.  Revised diagnostic criteria for the Marfan syndrome. , 1996, American journal of medical genetics.

[13]  R. Behringer,et al.  Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein , 1997, Nature.

[14]  D. Stafford,et al.  A Missense Mutation in γ-Glutamyl Carboxylase Gene Causes Combined Deficiency of All Vitamin K-Dependent Blood Coagulation Factors , 1998 .

[15]  P. Price,et al.  Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[16]  R H Myers,et al.  Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. , 1998, Circulation.

[17]  B. Dahlbäck,et al.  Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[18]  D. Stafford,et al.  A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. , 1998, Blood.

[19]  S E Humphries,et al.  Genetic determinants of arterial thrombosis. , 1994, Bailliere's best practice & research. Clinical haematology.

[20]  S. Kiechl,et al.  The natural course of atherosclerosis. Part II: vascular remodeling. Bruneck Study Group. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[21]  E. Tremoli,et al.  Tissue factor in atherosclerosis. , 1999, Atherosclerosis.

[22]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[23]  C. Vermeer,et al.  Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. , 2000, Blood.

[24]  A. Hofman,et al.  Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[25]  C. Vermeer,et al.  Novel mutation in the γ-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K–dependent blood coagulation factors , 2000 .

[26]  José A López,et al.  Cholesterol Sulfate: A New Adhesive Molecule for Platelets , 2001, Circulation.

[27]  Roger D. Kamm,et al.  The Impact of Calcification on the Biomechanical Stability of Atherosclerotic Plaques , 2001, Circulation.

[28]  G. London,et al.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[30]  Andreas Schober,et al.  Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E , 2003, Nature Medicine.

[31]  Platelets in Inflammation and Thrombosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[32]  R. Hui,et al.  Pentanucleotide TTTTA Repeat Polymorphism of Apolipoprotein(a) Gene and Plasma Lipoprotein(a) Are Associated With Ischemic and Hemorrhagic Stroke in Chinese: A Multicenter Case-Control Study in China , 2003, Stroke.

[33]  P. Tam.  The International HapMap Consortium. The International HapMap Project (Co-PI of Hong Kong Centre which responsible for 2.5% of genome) , 2003 .

[34]  Kiang Liu,et al.  Electron-Beam Tomography Coronary Artery Calcium and Cardiac Events: A 37-Month Follow-Up of 5635 Initially Asymptomatic Low- to Intermediate-Risk Adults , 2003, Circulation.

[35]  Yibo Wang,et al.  Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. , 2003, Stroke.

[36]  A. Khvorova,et al.  Identification of the gene for vitamin K epoxide reductase , 2004, Nature.

[37]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[38]  K. Berkner,et al.  The physiology of vitamin K nutriture and vitamin K‐dependent protein function in atherosclerosis , 2004, Journal of thrombosis and haemostasis : JTH.

[39]  M. Fornage,et al.  Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study , 2005, Human Genetics.

[40]  D. Tregouet,et al.  Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. , 2005, Blood.

[41]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[42]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[43]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[44]  M. Charng,et al.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. , 2005, Human molecular genetics.

[45]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[46]  M. Shearer,et al.  Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.

[47]  Yibo Wang,et al.  Vitamin K Epoxide Reductase: A Protein Involved in Angiogenesis , 2005, Molecular Cancer Research.

[48]  Tissue factor. , 2006, Seminars in thrombosis and hemostasis.